

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



JW (Cayman) Therapeutics Co. Ltd

藥明巨諾（開曼）有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2126)

**VOLUNTARY ANNOUNCEMENT
RESEARCH AND DEVELOPMENT UPDATE
LATEST CLINICAL DATA
ON CARTEYVA® IN FOLLICULAR LYMPHOMA
AND
MANTLE CELL LYMPHOMA AT THE 64th AMERICAN SOCIETY OF
HEMATOLOGY ANNUAL MEETING**

JW (Cayman) Therapeutics Co. Ltd (the “**Company**” or “**JW Therapeutics**”, together with its subsidiaries, the “**Group**”), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, presented the latest clinical data on Carteyva® (relmacabtagene autoleucel injection) (“**relma-cel**”, trade name: Carteyva®) in Chinese adults with relapsed/refractory follicular lymphoma (“**r/r FL**”) and relapsed/refractory mantle cell lymphoma (“**r/r MCL**”) at the 64th American Society of Hematology Annual Meeting.

Efficacy and Safety of relma-cel in Adults with Relapsed/Refractory Follicular Lymphoma in China (abstract number: 4640)

In this pivotal phase II RELIANCE study, patients who had histologically confirmed grade 1, 2, or 3a FL, with r/r disease were included. Eligible patients were randomized to receive relma-cel at the dose level of 100×10^6 or 150×10^6 chimeric antigen receptor T (“**CAR-T**”) cells, following lymphodepletion chemotherapy. As of the data cut-off date of December 17, 2021, based on 28 patients with 11.7 months of median follow-up, relma-cel demonstrated remarkable clinical responses achieving high rates of complete response rate (“**CRR**”) and overall response rate (“**ORR**”) (6 months ORR, CRR were 100% and 83.33% respectively), and a manageable safety profile (only 1 patient experienced Gr ≥ 3 neurotoxicity, no Gr ≥ 3 cytokine release syndrome (“**CRS**”). Updated safety and efficacy data with a longer follow-up will be presented.

Preliminary Safety and Efficacy of Relmacabtagene Autoleucel (relma-cel) in Adults with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL) in China (abstract number: 3326)

In this phase II single-arm open-label study in China, participants with MCL underwent ≥ 2 lines of therapy including anti-CD20 antibody, anthracycline or bendamustine, and BTKi were included. After lymphodepleting chemotherapy, participants received relma-cel (100×10^6 CAR-T cells). As of November 30, 2021, the preliminary data of relma-cel based on 11 patients provided promising clinical efficacy outcome (best ORR 81.8%, best CRR 54.5%) in high risk patients with r/r MCL and a low incidence of grade ≥ 3 CRS (1 patient) and immune effector cell-associated neurotoxicity syndrome (ICANS, 1 patient). This study is ongoing and further results will be presented.

About relma-cel (trade name: Carteyva[®])

Relma-cel (trade name: Carteyva[®]) is an autologous anti-CD19 CAR-T cell immunotherapy product independently developed by JW Therapeutics based on a CAR-T cell process platform of Juno Therapeutics, Inc. (a Bristol Myers Squibb company). Being the first product of JW Therapeutics, relma-cel has been approved by the China National Medical Products Administration for two indications, including the treatment of adult patients with r/r large B-cell lymphoma after two or more lines of systemic therapy, and the treatment of adult patients with follicular lymphoma that is refractory or that relapses within 24 months of second-line or above systemic treatment, making relma-cel (Carteyva[®]) the first CAR-T product approved as a Category 1 biologics product in China. Currently, relma-cel (Carteyva[®]) is the only CAR-T product in China that has been simultaneously included in the National Significant New Drug Development Program, priority review and breakthrough therapy designations.

About JW Therapeutics

JW Therapeutics (Stock Code: 2126) is an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, and is committed to becoming an innovation leader in cell immunotherapy. Founded in 2016, JW Therapeutics has built a world-class platform for product development in cell immunotherapy, as well as a product pipeline covering both hematologic malignancies, solid tumors and autoimmune diseases. JW Therapeutics is committed to bringing breakthrough and quality cell immunotherapy products and the hope of a cure to patients in China and worldwide, and leading the healthy and standardized development of China's cell immunotherapy industry.

For more information, please visit www.jwtherapeutics.com.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited: JW Therapeutics cannot guarantee that it will be able to develop, or ultimately market relma-cel successfully. Shareholders and potential investors of JW Therapeutics are advised to exercise due care when dealing in the shares of JW Therapeutics.

By order of the Board
JW (Cayman) Therapeutics Co. Ltd
藥明巨諾（開曼）有限公司*
Yiping James Li
Chairman

Shanghai, PRC, December 12, 2022

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Yiping James Li as Chairman and executive Director, Dr. Krishnan Viswanadhan, Ms. Xing Gao, Dr. Ann Li Lee, Mr. Jinyin Wang, Dr. Cheng Liu as non-executive Directors, and Mr. Chi Shing Li, Mr. Yiu Leung Andy Cheung, Mr. Kin Cheong Kelvin Ho as independent non-executive Directors.

* *For identification purpose only*